Treatment of solid P815x2 murine mastocytoma with adriamycin (NSC-1231127): toxity limitations.
The efficacy of adriamycin (NSC-123127), given as weekly or as 5-day-per-week doses, on the control of solid P815X2 murine mastocytomas was severely limited by hematopoietic and gastrointestinal toxicity. Although daily or weekly drug schedules both elicited dose responsiveness in terms of tumor control, no dose level of drug increased the life-span of tumor bearing animals.
D000818:Animals; D004317:Doxorubicin / Q000627:therapeutic use* / Q000633:toxicity; D008297:Male; D012515:Mast-Cell Sarcoma / Q000188:drug therapy*; D051379:Mice; D008811:Mice, Inbred DBA; D009374:Neoplasms, Experimental / Q000188:drug therapy
D004317:Doxorubicin